Designing and developing an advanced smart inhalation device

The “Just Breathe” project: A collaboration between Unitron Systems and Gilbert Innovation

This project is made possible in part with financial support from the European Union, with an awarded subsidy within the OPZuid 2021-2027 program.

As part of the “Just Breathe” project, Unitron Systems and Gilbert Innovation are joining forces to design and develop an advanced smart inhalation device (TRL 7) for the treatment of various lung diseases. Gilbert’s patented electrospray technology is being integrated into the device to enable effective atomization and targeted delivery of drugs to the appropriate regions of the lungs. Smart software features will allow for adherence monitoring, potentially reducing the need for in-person doctor visits. This development is expected to bring significant benefits to patients, healthcare providers, and the broader healthcare system.

Once the device is ready for CE marking, the consortium will begin development of a first drug-device combination tailored for cystic fibrosis treatment. This will include replaceable drug reservoirs designed for each patient’s individual medication. Sustainability is also a priority: the consortium aims for a circular design to help minimize the healthcare sector’s carbon footprint.

Gilbert’s role in the project is critical due to their extensive expertise in electrospray technology and pulmonary drug formulation. Over recent years, they have been further developing this technology, and in this project, they will focus on advancing a multi-nozzle spray head and creating specific formulations for the device.

Unitron is responsible for the design and development of the smart inhaler. With our extensive experience in medical product manufacturing and established industry reputation, we play a key role in developing the prototype.

Both partners are based in the southern region of the Netherlands. This project strengthens the local economy and knowledge infrastructure, enhancing not only the competitive position of the participating companies but also that of the region as a hub for promising and impactful medical innovations.

Innovencio is involved within this project as subsidy advisor